QL Biopharm Announces Abstract on Novel Ultra Long-acting GLP-1RA to be Presented at EASD Annual Meeting 2024
– Abstract on data from a two-part phase 1c, multiple ascending dose study accepted for oral presentation –
– New data highlighting the Company’s lead drug candidate ZT002 for obesity –
Beijing, China, 3 September 2024 – Beijing QL Biopharmaceutical Co., Ltd. (“QL Biopharm”), a clinical stage biopharmaceutical company developing innovative biologic drugs for the treatment of metabolic diseases, today announces that an abstract on its lead drug candidate ZT002 will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024, Madrid, Spain on Thursday 12 September 2024.
